Q2:n perusteella Implantican Euroopan liiketoiminta kehittyy oikeaan suuntaan samaan aikaan, kun FDA-hyväksyntä avasi USA:n markkinan.
Q2-liikevaihto kasvoi 66 % → 0,717 M€ ja H1-liikevaihto 34 % → 1,574 M€. Lähtötaso on edelleen pieni, mutta kasvuvauhti on lupaava. Erityisen kiinnostava on 94 %:n bruttomarginaali, joka kertoo RefluxStopin erittäin hyvästä yksikkötaloudesta.
EBIT oli edelleen -4,2 M€, mutta kassassa oli kvartaalin lopussa 41,7 M€. USA:n organisaation rakentaminen tulee todennäköisesti kasvattamaan kustannuksia lähiaikoina, joten kassankulutusta kannattaa seurata.
Kliininen näyttö vahvistui myös merkittävästi: 602 potilaan ja 22 keskuksen riippumattomassa tutkimuksessa vakavat turvallisuustapahtumat ja uusintaleikkaukset jäivät alle 2 %:iin. Euroopassa Center of Excellence -verkosto on kasvanut jo yli 60 keskukseen.
Implantica publishes Interim Report January – June 2026 (Q2)
logo
Implantica publishes Interim Report January – June 2026 (Q2)
FDA Approval of RefluxStop® – Strategic Preparation Sets the Stage for Success
Significant events in the second quarter of 2026
RefluxStop® sales increased by more than 60% compared with the prior-year period, reflecting continued commercial growth across key European markets
Largest independent RefluxStop® study to date published in Nature’s Scientific Reports, reporting mid- to long-term safety outcomes in 602 patients across 22 centers in six European countries, with serious safety events and reoperations below 2%
Clinical, health-economic and reimbursement evidence further strengthened, including new Italian cost-effectiveness data and the addition of a seventh InEK-reporting hospital in Germany supporting the reimbursement pathway
Significant events after the end of the period
FDA PMA approval secured for RefluxStop®, opening the U.S. market and enabling the start of U.S. commercial launch activities
U.S. market entry underway, with expansion of the U.S. organization and establishment of logistics and distribution infrastructure
European market presence continued to expand, including the 20th Center of Excellence in Spain at MD Anderson Madrid and new Centers in Switzerland and the UK, bringing the European network to more than 60 Centers of Excellence
Financial summary second quarter
Net sales increased by 66% to TEUR 717 (433).
Adjusted gross margin amounted to 94% (90%).
Operating loss (EBIT) decreased to TEUR 4,200 (4,525).
Loss after tax amounted to TEUR 3,987 (5,448).
Basic and diluted loss per Class A share amounted to EUR 0.06 (0.08).
Cash and cash equivalents as at the end of the period of MEUR 41.7.
Financial summary first six months
Net sales increased 34% to TEUR 1,574 (1,178).
Adjusted gross margin amounted to 94% (94%).
Operating loss (EBIT) decreased to TEUR 8,058 (8,698).
Loss after tax amounted to TEUR 8,267 (8,212).
Basic and diluted loss per Class A share amounted to EUR 0.12 (0.12).